Detectable viral load in late pregnancy among women in the Rwanda option B+ PMTCT program: Enrollment results from the Kabeho Study

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Gill, Michelle M ^a   Hoffman, Heather J ^b   Bobrow, Emily A ^a   Mugwaneza, Placidie ^c   Ndatimana, Dieudonne ^a   Ndayisaba, Gilles F ^a   Baribwira, Cyprien ^d   Guay, Laura ^a,b   Asiimwe, Anita ^e  

^a ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Rwanda Ministry of Health   (Rwanda)

^d UNIVERSITY OF MARYLAND   (United States)

^e Rwanda University Teaching Hospitals (CHU)   (Rwanda)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ADVERSE OUTCOME; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; EDUCATIONAL STATUS; FEMALE; GENOTYPE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREGNANCY; PUERPERIUM; RWANDA; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; VERTICAL TRANSMISSION; VIREMIA; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREVALENCE; PROSPECTIVE STUDIES; RWANDA; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 85007388054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168671     Document Type: Article

References (27)

1. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO Department of HIV/AIDS;2013.
2. Rwanda Biomedical Center. National Guidelines for Prevention and Management of HIV, STIs & Other Blood Borne Infections. Kigali, Rwanda: Ministry of Health, Republic of Rwanda; 2013.
3. Hoffman RM, Black V, Technau K, van der Merwe KJ, Currier J, Coovadia A, et al. Effects of Highly Active Antiretroviral Therapy Duration and Regimen on Risk for Mother-to-Child Transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2010; 54: 35-41. doi: 10.1097/QAI. 0b013e3181cf9979 PMID: 20216425
4. Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, et al. Optimal Time on HAART for Prevention of Mother-to-Child Transmission of HIV. J Acquir Immune Defic Syndr. 2011; 58: 224-8. doi: 10.1097/QAI.0b013e318229147e PMID: 21709566
5. Townsend C, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014; 28: 1049-1057. doi: 10.1097/QAD.0000000000000212 PMID: 24566097
6. Warszawski J, Tubianae R, Le Chenadeca J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008; 22: 289-299. doi: 10.1097/QAD.0b013e3282f3d63c PMID: 18097232
7. Mandelbrot L, Tubiana R, Le Chenadec, J, Dollfus C, Faye A, Rouzioux C, et al. No perinatal transmission of HIV-1 in women efficiently treated since conception. Abstract presented at the Conference on Retroviruses and Opportunistic Infections; Seattle, Washington, USA; 2015 Feb 23-26.
8. Myer L, Phillips T, Ramjith J, Bekker LG, McIntyre JA, and Abrams EJ. Viral Suppression After Antiretroviral Therapy Initiation in Pregnancy in South Africa. Abstract presented at the Conference on Retroviruses and Opportunistic Infections; Seattle, Washington, USA; 2015 Feb 23-26.
9. Denoeud-Ndam L, Fourcade C, Ogouyemi-Hounto A, Azon-Kouanou A, d'Almeida M, Azondékon A, et al. Predictive factors of plasma HIV suppression during pregnancy: a prospective cohort study in Benin. PloS ONE. 2013; 8: e59446. doi: 10.1371/journal.pone.0059446 PMID: 23555035
10. Read PJ, Mandaliab S, Khan P, Harrisson U, Naftalin C, Gilleece Y, et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS. 2012; 26: 1095-1103. doi: 10.1097/QAD.0b013e3283536a6c PMID: 22441248
11. Patel D, Cortina-Borja M, Thorne C, and Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007; 44: 1647-1656 doi: 10.1086/518284 PMID: 17516411
12. Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, et al. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation. BJOG.2013; 120: 1534-1547. doi: 10.1111/1471-0528.12226 PMID: 23924192
13. Myer L, Phillips TK, Hsiao NY, Zerbe A, Petro G, Bekker LG, et al. Plasma viraemia in HIV-positive pregnant women entering antenatal care in South Africa. J Int AIDS Soc. 2015; 18:20045. doi: 10.7448/ IAS.18.1.20045 PMID: 26154734
14. Myer L, Phillips TK, McIntyre JA, Hsiao NY, Petro G, Zerbe A, et al. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa. HIV Med. 2016.
15. Mancinelli S, Galluzzo CM, Andreotti M, Liotta G, Jere H, Sagno JB, et al. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. AIDS Res Hum Retroviruses. 2016; 32:737-42. doi: 10.1089/AID.2015.0366 PMID: 27067142
16. Haas AD, Msukwa MT, Egger M, Tenthani L, Tweya H, Jahn A, et al. Adherence to antiretroviral therapy during and after pregnancy: Cohort study on women receiving care in Malawi's "Option B+" programme. Clinical Infectious Disease, Epub, 2016.
17. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland: WHO Department of HIV/AIDS;2015.
18. Stanford HIV Drug Resistance Database. Major HIV-1 Drug Resistance Mutations. 2015. https://hivdb. stanford.edu/pages/download/resistanceMutations-handout.pdf
19. Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, et al. Risk Factors for Detectable HIV-1 RNA at Delivery Among Women Receiving Highly Active Antiretroviral Therapy in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2010; 54: 27-34. doi: 10.1097/QAI. 0b013e3181caea89 PMID: 20065861
20. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS ONE. 2015; 10: e0116144. doi: 10.1371/ journal.pone.0116144 PMID: 25695494
21. Stadeli KM, Richman DD. (2012). Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2012; 18:115-23. doi: 10.3851/IMP2437 PMID: 23052978
22. Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, et al. Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr. 2016; 71:31-7. doi: 10.1097/QAI.0000000000000811 PMID: 26334739
23. Ngarina M, Kilewo C, Karlsson K, Aboud S, Karlsson A, Marrone G, et al. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. BMC Infect Dis. 2015; 15:175. doi: 10.1186/s12879-015-0914-z PMID: 25886277
24. Labhardt ND, Bader J, Ramoeletsi M, Kamele M, Lejone TI, Cheleboi M, et al. Clinical and socio-demographic predictors for virologic failure in rural Southern Africa: preliminary findings from CART-1. J Int AIDS Soc. 2014; 17(4 Suppl 3): 19666. doi: 10.7448/IAS.17.4.19666 PMID: 25397416
25. Jasseron C, Mandelbrot L, Dollfus C, Trocmé N, Tubiana R, Teglas JP, et al. Non-Disclosure of a Pregnant Woman's HIV Status to Her Partner is Associated with Non-Optimal Prevention of Mother-to-Child Transmission. AIDS Behav. 2013; 17: 488-97. doi: 10.1007/s10461-011-0084-y PMID: 22130651
26. Musiime S, Muhairwe F, Rutagengwa A, Mutimura E, Anastos K, Hoover DR, et al. Adherence to Highly Active Antiretroviral Treatment in HIV-Infected Rwandan Women. PLoS ONE. 2011; 6: e27832. doi: 10. 1371/journal.pone.0027832 PMID: 22114706
27. Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012; 366: 2368-79. doi: 10. 1056/NEJMoa1108275 PMID: 22716975